Research
Hormonal
Brown adipose tissue thermogenesis is strictly dependent on lipolysis; thermogenesis cannot be evoked without simultaneously evoking lipolysis, and fatty acids released from triglycerides act as the direct trigger for UCP1.
Brown fat burns energy by breaking down stored fats (lipolysis). The released fatty acids directly activate the UCP1 protein to generate heat. You cannot have brown fat heat production without first breaking down fat stores.
StrongSupportsVERY_HIGH confidence
all manipulations that induce lipolysis in brown adipocytes also induce thermogenesis, and no thermogenesis can be evoked without simultaneously evoking lipolysis.
Why this rating
Supported by consistent experimental observations across multiple studies cited.
Source
Brown Adipose Tissue: Function and Physiological Significance
Barbara Cannon et al. · Physiological Reviews · 2004
DOI 10.1152/physrev.00015.2003
narrative_reviewCited 6,368×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Brown adipose tissue (BAT) thermogenesis is exclusively mediated by uncoupling protein-1 (UCP1) and requires lipolysis-derived fatty acids as the trigger; in the absence of UCP1, norepinephrine-induced thermogenesis does not occur.Strong
- Beta-3 adrenergic receptors are not strictly required for brown adipose tissue function or thermogenesis, as evidenced by species lacking them (guinea pigs) or mice genetically ablated for beta-3 receptors, which compensate via beta-1 receptors.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →